Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes.
Inhibition of bile acid (BA) transport may contribute to the hepatotoxicity of troglitazone (TRO), a peroxisome proliferator-activated receptor gamma agonist. Typically, studies use taurocholic acid (TCA) as a model substrate to investigate effects of xenobiotics on BA disposition. However, TRO may differentially affect the transport of individual BAs, potentially causing hepatocyte accumulation of more cytotoxic BAs. The effects of TRO on the disposition of [(14)C]-labeled chenodeoxycholic acid ([(14)C]CDCA), an unconjugated cytotoxic BA, were determined in suspended hepatocytes and sandwich-cultured hepatocytes (SCH) from rats. (E)-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-propanoic acid (MK571), a multidrug resistance-associated protein (MRP) inhibitor, was included to evaluate involvement of MRPs in CDCA disposition. Accumulation in cells + bile of total [(14)C]CDCA species in SCH was sixfold greater than [(3)H]TCA and unaffected by 1 and 10μM TRO; 100μM TRO and 50μM MK571 ablated biliary excretion and significantly increased intracellular accumulation of total [(14)C]CDCA species. Results were similar in Mrp2-deficient TR(-) rat hepatocytes. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis revealed that taurine- and glycine-conjugated CDCA, in addition to unconjugated CDCA, accumulated in hepatocytes during the 10-min incubation. In suspended rat hepatocytes, initial [(14)C]CDCA uptake was primarily Na(+)-independent, whereas initial [(3)H]TCA uptake was primarily Na(+)-dependent; TRO and MK571 decreased [(14)C]CDCA uptake to a lesser extent than [(3)H]TCA. Unexpectedly, MK571 inhibited Na(+)-taurocholate cotransporting polypeptide and bile salt export pump. Differential effects on uptake and efflux of individual BAs may contribute to TRO hepatotoxicity. Although TCA is the prototypic BA used to investigate the effects of xenobiotics on BA transport, it may not be reflective of other BAs.
Curriculum in Toxicology, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7270, USA.
Tracy L
TL
Marion
Cassandra H
CH
Perry
Robert L
RL
St Claire
Wei
W
Yue
Kim L R
KL
Brouwer
D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors / Q000235:genetics; D000818:Animals; D001692:Biological Transport; D002250:Carbon Radioisotopes; D002478:Cells, Cultured; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology / Q000378:metabolism; D002635:Chenodeoxycholic Acid / Q000378:metabolism*; D002839:Chromans / Q000633:toxicity*; D002851:Chromatography, High Pressure Liquid; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D047495:PPAR gamma / Q000819:agonists*; D011422:Propionates / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D053719:Tandem Mass Spectrometry; D013656:Taurocholic Acid / Q000378:metabolism*; D045162:Thiazolidinediones / Q000633:toxicity*; D000077288:Troglitazone
D018528:ATP-Binding Cassette Transporters; C423013:Abcc2 protein, rat; D002250:Carbon Radioisotopes; D002839:Chromans; D047495:PPAR gamma; D011422:Propionates; D011804:Quinolines; D045162:Thiazolidinediones; D002635:Chenodeoxycholic Acid; D013656:Taurocholic Acid; C059141:verlukast; D000077288:Troglitazone
Toxicol Lett. 1992 Jul;61(2-3):291-304
1641875
Hepatology. 2001 Aug;34(2):351-9
11481620
Semin Liver Dis. 2000;20(3):273-92
11076396
Hepatol Res. 2008 Mar;38(3):300-9
17760873
Biochem Med. 1973 Oct;8(2):280-6
4753210
Semin Liver Dis. 2010 May;30(2):178-85
20422499
Toxicology. 2001 Oct 5;167(1):83-98
11557132
Pharmacogenomics J. 2008 Feb;8(1):42-52
17404579
J Pharmacol Exp Ther. 2006 Sep;318(3):1068-75
16720753
Dig Dis Sci. 1984 Dec;29(12):1123-30
6499631
J Hepatol. 2005 Aug;43(2):342-57
15975683
Biochem Pharmacol. 1982 Jan 15;31(2):211-6
7059363
Mol Pharmacol. 2001 Mar;59(3):627-35
11179459
Semin Liver Dis. 2010 May;30(2):147-59
20422497
J Lipid Res. 2006 Jun;47(6):1196-202
16534140
Biochim Biophys Acta. 1983 Nov 1;754(1):101-9
6626562
J Pharmacol Exp Ther. 2010 Aug;334(2):410-8
20430841
Pflugers Arch. 2007 Feb;453(5):661-73
16586096
J Biol Chem. 1998 Apr 17;273(16):10046-50
9545351
Lab Invest. 2002 Feb;82(2):193-201
11850532
Drug Metab Dispos. 2009 Sep;37(9):1878-86
19520776
J Hepatol. 2004 Apr;40(4):585-91
15030973
Toxicol Sci. 2010 May;115(1):80-8
20147439
J Pharmacol Exp Ther. 2007 Jun;321(3):1170-8
17374746
Gastroenterology. 2004 Jan;126(1):322-42
14699511
J Pharmacol Exp Ther. 2005 May;313(2):549-56
15665139
Comp Biochem Physiol B. 1986;83(3):551-4
3956167
Pharmacotherapy. 2010 Jan;30(1):17-24
20030469
Am J Physiol. 1975 Aug;229(2):298-302
1163658
Life Sci. 2007 Jan 30;80(8):732-40
17126857
Nat Rev Drug Discov. 2008 Aug;7(8):678-93
18670431
Toxicol Sci. 2005 Feb;83(2):207-14
15509663
Clin Chem Lab Med. 2003 Dec;41(12):1633-41
14708888
Toxicol Sci. 2006 May;91(1):140-9
16495352
Biochim Biophys Acta. 1999 Dec 6;1461(2):377-94
10581368
Drug Metab Dispos. 2010 Feb;38(2):276-80
19910518
Hepatology. 2001 May;33(5):1223-31
11343252
Gastroenterology. 2002 Nov;123(5):1649-58
12404239
Hepatology. 1995 Aug;22(2):637-47
7635434
Physiol Rev. 2003 Apr;83(2):633-71
12663868
Toxicol In Vitro. 2010 Feb;24(1):297-309
19706322
Hoppe Seylers Z Physiol Chem. 1975 Jun;356(6):827-38
241693
Drug Metab Pharmacokinet. 2006 Oct;21(5):347-56
17072088
Am J Physiol. 1982 Dec;243(6):G484-92
7149031
Mol Pharm. 2007 Nov-Dec;4(6):911-8
17963355
J Pharmacol Exp Ther. 1999 Jun;289(3):1592-9
10336557